ERBB2 and breast cancer: In pre-clinical models, dual-targeting CAR-T cells specific to co-expressing HER2 and MUC-1 effectively killed HER2+ breast cancer cells expressing these targets (62), HER2-redirected CAR-T cells eliminated HER2+ trastuzumab-sensitive tumor cell lines (SKBR3 and BT474).